NCT00688090View on ClinicalTrials.gov

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

May 31, 2010

Conditions
Advanced MelanomaStage III and IV Melanoma
Interventions
BIOLOGICAL

Biological: MKC1106-MT

Cancer Vaccine, Immunotherapy

BIOLOGICAL

Biological: MKCC1106-MT

Cancer Vaccine, Immunotherapy

Trial Locations (2)

33612

H Lee Moffitt Cancer Center University of So Florida, Tampa

90034

UCLA Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY